The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program.
Grants of up to $600,000 over two years will be awarded in support of promising preclinical drug discovery programs relevant to Alzheimer’s disease, related dementias, and cognitive aging. Preclinical research funding priorities include high through-put screening, medicinal chemistry hit-to-lead development (and lead optimization), in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics.
Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuroinflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities.
To be eligible, applicants must be an academic investigator seeking to create and support an innovative translational program in an academic medical center or university; a biotechnology company with programs dedicated to Alzheimer's disease translational development; or a new biotechnology company spinout or existing biotechnology company with a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require return on investment based on scientific and/or business milestones.
Letters of Intent must be received no later than May 19, 2017. Upon review, selected applicants will be invited to submit a full proposal by June 9, 2017.
For complete program guidelines and application instructions, see the ADDF website.